2025 third_quarter Filing
Q3Lobbying Activities
FDA drug approval, importation. Monitoring of changes to prescription drug advertising. PBM reform proposals, NIH funding, support and clinical trials.
H.R. 1, One Big Beautiful Bill Act, issues related to R&D tax credit. Monitor trade and tariff issues related to pharmaceutical tariffs. Health care IP.